Press releases

PRESS RELEASE - Salem, MA, USA - October 3rd, 2023 Genoskin introduces ImmunoSafe: ISR Platform® with AUDACY - A revolutionary leap in non-clinical local toxicity assessment Salem, MA, October 3rd, 2023 - Genoskin, a biotechnology company at the forefront of accelerating drug development, proudly announces the enhancement of its ISR Platform® with the integration of AUDACY, a state-of-the-art bioinformatics-based analyticalRead more

PRESS RELEASE - Toulouse, France - June 8th, 2023 Introducing MANTIS®: A Breakthrough Analytic Pipeline for Unraveling the Complexity of Inflammatory Skin Conditions. Toulouse, France, June 8, 2023 - Genoskin is proud to announce the publication of a groundbreaking scientific article in Science Advances, introducing a new analytic pipeline called MANTIS® (Multiplexed Annotated Tissue Imaging System). The article, authored byRead more

PRESS RELEASE - Washington D.C. - April 3, 2023 Genoskin and PharmaJet announce strategic research partnership to advance precision vaccine delivery Washington D.C., April 3, 2023 - Genoskin, a leading Franco-American TechBio company specializing in bio-stabilized immunocompetent human skin platforms, and PharmaJet, an innovative provider of Precision Delivery Systems (PDS), announce a strategic research partnership during the World Vaccine Congress.Read more

PRESS RELEASE - Toulouse, France - May 2022 Dr. Florent Ginhoux joins Genoskin’s Scientific Advisory Board Genoskin is thrilled to welcome Dr. Florent Ginhoux, PhD, to its Scientific Advisory Board (SAB). After last year's nomination of world-renowned immunology expert, Dr. Nicolas Gaudenzio, as Genoskin’s CSO, Dr. Ginhoux will now bring his world-class expertise as Highly Cited Researcher in tissue-resident immuneRead more

PRESS RELEASE - Toulouse, France & Salem, MA, USA - December 6, 2021 GENOSKIN LAUNCHES SPATIAL SKIN BIOLOGY PLATFORM MANTIS® Genoskin launches MANTIS®, a spatial biology imaging platform dedicated to skin immunology. The MANTIS® (Multiplex ANnotated Tissue Imaging System) platform was developed at Infinity (Inserm U1291, France) by a team of experts under the guidance of Dr. Nicolas Gaudenzio, whoRead more

Genoskin appoints Dr Nicolas Gaudenzio as Chief Scientific Officer Today, November 8, Genoskin announces the appointment of Dr. Nicolas Gaudenzio as Chief Scientific Officer (CSO), starting in November. Dr. Gaudenzio will lead Genoskin's shift towards new activities Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of aRead more